Elutia Inc. (NASDAQ: ELUT) shares tumbled Friday. The Silver Spring, Md. company, a pioneer in drug-eluting biomatrix technologies, today announced that EluPro™, the first ever FDA-cleared antibiotic-eluting bioenvelope was honored with a 2025 Bronze Edison Award™ for its innovative approach to reducing post-surgical complications.
The 2025 finalists were selected from thousands of submissions, rigorously evaluated on concept, value, delivery, and impact. The selection process was led by the Edison Awards Steering Committee and an independent panel of experts, including scientists, engineers, designers, and business leaders.
“It’s an incredible honor to accept this award on behalf of Elutia and to see EluPro recognized alongside some of the most innovative products in the world,” said CEO Randy Mills.
“This isn’t just a prestigious award—it’s a reflection of our team’s ridiculously relentless commitment to solving real problems for real people.”
Launched in January 2025, EluPro is cleared for use across all major cardiac implanted electronic device (CIED) products including pacemakers and implantable defibrillators, as well as for neurostimulation devices. Unlike synthetic alternatives, EluPro combines a soft, regenerative biomatrix with the trusted antibiotics rifampin and minocycline to address CIED complications and support healthy healing.
With more than 600,000 CIEDs implanted annually in the U.S. and complications—such as infection, migration, and skin erosion—occurring in up to 5-7% of cases, the need for improved outcomes is clear. EluPro provides a comprehensive solution for both patients and clinicians.
ELUT shares lost 17 cents, or 5.8%, to $2.74.
